Peptide half-life basics: why some peptides last longer than others
How long a peptide stays in the body isn't arbitrary — it follows from the structure of the molecule.
TL;DR
- Half-life is the time it takes for the concentration of a compound in the body to fall by 50% — it describes how long a compound stays in circulation.
- Unmodified peptides such as ipamorelin are short-acting: the body clears them quickly.
- In a study in healthy adults, CJC-1295 with DAC had a half-life of approximately 6 to 8 days, because the DAC modification slows clearance.
What it is
Half-life (t½) is a pharmacokinetic concept: the time required for the plasma concentration of a compound to decrease by half from its peak. It is one of the most fundamental parameters in clinical pharmacology — it tells a pharmacologist how quickly a drug is cleared from the body.
For most unmodified peptides, half-life is short. The body recognizes peptide bonds and breaks them down via circulating enzymes called peptidases. A peptide injected subcutaneously may reach peak concentration quickly and be largely cleared within hours.
How it works
The half-life equation has a simple consequence: a compound with a 30-minute half-life drops to 12.5% of its peak concentration within 90 minutes. A compound with a 7-day half-life is still at roughly 50% of its peak one week later.
CJC-1295 illustrates the contrast well. The base molecule, CJC-1295 without DAC, has a short half-life. Adding a Drug Affinity Complex (DAC) — a technology that allows the molecule to bind to albumin in the bloodstream — extends the half-life to approximately 6 to 8 days, as reported in a pharmacokinetic study in healthy adults (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006). That single modification changes how long the molecule stays in circulation.
Who asks about it
People come to this topic after reading that some peptides clear from the body within hours while others, like CJC-1295 with DAC, last for days. The answer is half-life, and the chemistry that sets it.
What the research says
The Teichman et al. 2006 study in the Journal of Clinical Endocrinology & Metabolism remains the primary pharmacokinetic reference for CJC-1295 with DAC in humans. The study reported sustained GH elevation following a single dose, with a half-life of approximately 6 to 8 days.
Ipamorelin is short-acting by comparison. It was first described in animal studies by Raun et al. in 1998 (Raun et al., European Journal of Endocrinology, 1998).
What half-life does not tell you
Half-life describes how long a compound stays in the blood. It does not show whether a compound works, or whether it is safe for any one person. For CJC-1295 and ipamorelin, the published human data are small and short-term, and neither compound is approved by FDA for any use.
The Halftime POV
Half-life looks like pharmacology-class detail, but it explains a lot of what people read about peptides. A small change to a molecule, like adding DAC to CJC-1295, can stretch its time in the body from hours to days. Knowing that helps you read peptide claims with a sharper eye: a longer half-life is a property of the molecule, not evidence that it works.
Related reading:
FAQ
Q: What is peptide half-life? A: Half-life (t½) is the time required for the plasma concentration of a compound to decrease by 50% from its peak. It describes how long a compound stays in circulation. Most unmodified peptides have short half-lives — minutes to a few hours — because the body's peptidases break them down rapidly.
Q: Why does CJC-1295 with DAC have a longer half-life than regular CJC-1295? A: Adding a Drug Affinity Complex (DAC) allows the CJC-1295 molecule to bind to albumin in the bloodstream, dramatically slowing clearance. The non-DAC version has a short half-life; the DAC version has a half-life of approximately 6–8 days, as documented by Teichman et al. in the Journal of Clinical Endocrinology & Metabolism, 2006.
Q: Does a longer half-life make a peptide better? A: No. Half-life describes how long a compound stays in the blood. It does not show whether the compound works or whether it is safe. A long-acting and a short-acting peptide produce different concentration curves over time, and that is all half-life tells you.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved.
Sources
- Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998.
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What is peptide half-life?
Half-life (t½) is the time required for the plasma concentration of a compound to decrease by 50% from its peak. It describes how long a compound stays in circulation. Most unmodified peptides have short half-lives — minutes to a few hours — because the body's peptidases break them down rapidly.
Why does CJC-1295 with DAC have a longer half-life than regular CJC-1295?
Adding a Drug Affinity Complex (DAC) allows the CJC-1295 molecule to bind to albumin in the bloodstream, dramatically slowing clearance. The non-DAC version has a short half-life; the DAC version has a half-life of approximately 6–8 days, as documented by Teichman et al. in the Journal of Clinical Endocrinology & Metabolism, 2006.
Does a longer half-life make a peptide better?
No. Half-life describes how long a compound stays in the blood. It does not show whether the compound works or whether it is safe. A long-acting and a short-acting peptide produce different concentration curves over time, and that is all half-life tells you.
